sites for PAR-2, PAR-3, and PAR-4 are SKGR/S, LPIK/T, and PAPR/G, respectively. The tethered ligand domains are SLIGKV for PAR-2, TERGAP for activating PAR-3, and GYPGQV for activating PAR-4. In addition to the protease cleavage sites, the NH 2 terminal DKYEPF hirudin-like domain in PAR-1 also plays an important role in facilitating the interaction of thrombin with the receptor. The extracellular loop-2, where the tethered ligand and receptor interaction occurs, is composed of 24 amino acids that are conserved among different species. The cytoplasmic COOH terminus of PAR-1 also contains sequences that are involved in desensitization and intracellular signaling (16) .
Based on the PAR activation mechanism and the sequences of the tethered ligand domains and the extracellular loop-2, many synthetic PAR-activating peptides have been designed and demonstrated to be able to activate PARs without cleavage of the NH 2 terminus. For example, the thrombin receptor activating peptide (TRAP) is able to interact with the extracellular loop-2 of PAR-1 via its SFLLRN domain, activates the receptor, and stimulates downstream signaling cascades. Although many different PAR-activating peptides (which include the sequences of the tethered ligand domains) are all effective in activating the receptors, the composition of amino acids and the threedimensional structure of the peptides significantly alter the efficacy and potency for activation of the receptors (16) .
Similar to other G protein-coupled receptors, the downstream signaling cascades of PARs include many kinases and intracellular messengers, such as 1) G q/11 -mediated increase in cytoplasmic free Ca 2ϩ ([Ca 2ϩ ] cyt ) by inositol 1,4,5-trisphosphate and diacylglycerol and activation of PKC and calmodulin kinases (CaMKII and CaMKIV); 2) G 12/13 -mediated activation Rho/Rho kinase and c-Jun NH 2 -terminal kinase; and 3) G 12␤␥ -mediated Ras/MAPK and PKB. The systemic, tissue, and cellular effects of the serine protease-mediated PAR activation include platelet aggregation, cell proliferation, prostanoid synthesis and release, cytokine production, smooth muscle contraction and mitogenesis, endothelial release of von Willebrand factor and nitric oxide, inhibition of keratinocyte differentiation, neuronal apoptosis, and procollagen production (1, 6, 16, 18) . In airway smooth muscle cells and in pulmonary vascular fibroblasts, PAR-1-mediated activation of p70 s6k and PKB is related to phosphatidylinositol 3-kinase. PKB and P70 s6k are two important regulators of cell survival and proliferation (3, 13, 15, 23) . Thrombin-mediated activation of PAR-1 has been shown to stimulate the tyrosine phosphorylation of the growth factor receptors, activate MAPK cascade, stimulate transactivation of growth factor receptors, promote cell survival, and enhance mitogenesis.
Classically, serine proteases (e.g., thrombin, trypsin, mast cell tryptase) play important roles in diverse biological functions, including clot formation and wound healing (16) . Originally identified as a key mediator of the coagulation cascade and a potent activator of platelet aggregation, thrombin has been identified as a physiological activator of PAR-1 and PAR-2. More recently, studies have shown that thrombin may also contribute to the development of pulmonary fibrosis and acute lung injury (9, 10), primarily via PAR-1 activation. In a similar study, pharmacological activation of PAR-1 and PAR-2 by agonist peptides, or TRAP, has also been linked to the production of cytokines (IL-6, IL-8) in inflamed lungs (2) . In the vasculature itself, thrombin has effects on all cell types that make up the arterial wall. In the tunica intima, thrombin triggers 1) endothelial cell rounding (increasing permeability), 2) endothelial cell migration, and 3) endothelial production of cytokines, growth factors, and matrix proteins (14, 20) . At a more basic level, thrombin signaling appears to involve PAR-1 (and PAR-4) activation, elevating [Ca 2ϩ ] cyt levels and causing ERK phosphorylation, and enhancing the expression of early growth response 1 and c-Fos, two immediate early genes that have been implicated in inflammation and tissue remodeling in response to injury (14) . In support of this finding, another study has suggested that activated protein C, which activates PAR-1, can inhibit hypoxia-induced human brain endothelial cell apoptosis (5), casting PAR-1 activation in a neuroprotective role. In the tunica media, thrombin enhances smooth muscle proliferation (11, 21) and causes endothelium-dependent relaxation (8), the latter being coupled to activation of PAR-1 or a PAR-1-like receptor in human pulmonary arteries.
Although PAR-1 activation by thrombin promotes pulmonary fibrosis due to fibroblast proliferation and differentiation, there is evidence that PAR-1 and PAR-2 activation may also stimulate airway epithelial cell production of PGE 2 , an antifibrotic mediator (2) . In the report from Sokolova et al., one of the current articles in focus (Ref. 19 , see p. L793 in this issue), the authors examine the cyclical relationship between PAR activation and PGE 2 production in thrombin-induced pulmonary fibroblast activation. Their data show that, although PAR-2 is upregulated, PAR-1 and -3 are unchanged in fibrotic fibroblasts, suggesting that PAR-2 may be important in the development of fibroproliferative disorders. In thrombin-and trypsin-treated cells, PAR-1 activation caused transient cathepsin-regulated Ca 2ϩ increases in lung fibroblasts. Both PAR-1 and -3 activation (by thrombin and thrombin receptor agonist, respectively) dose dependently enhanced PGE 2 release via cyclooxygenase-2 (COX-2) production. This increase in PGE 2 was diminished in thrombin-treated fibrotic fibroblasts. Finally, thrombin-induced PAR-1 upregulation is significantly reduced by PGE 2 application, the latter acting via E-prostanoid 2 (EP2) receptors and cAMP production. Therefore, PGE 2 synthesis, in addition to its role in limiting cell proliferation and collagen synthesis, serves a novel protective role in preventing lung fibroblast activation by thrombin, further repressing lung fibrosis.
Using tissue samples from patients undergoing diagnostic open lung biopsy or pneumonectomia for tumor resection, Sokolova et al. (19) provide compelling evidence that 1) normal lung fibroblasts express PAR-1, PAR-2, and PAR-3; 2) PAR-2 is significantly upregulated in fibrotic fibroblasts compared with normal fibroblasts, although the relative expression level in both normal and fibrotic fibroblasts is lower than in Fig. 1 . Schematic diagram depicting the potential mechanisms involved in thrombin-mediated fibroblast proliferation and the PGE2-mediated negative feedback effect on the fibrotic effects of thrombin and other serine proteases. Multiple mechanisms promote or enhance (circled plus sign) pulmonary fibroblast proliferation and migration, whereas only prostanoid E2 (EP2) receptor stimulation acts as a negative feedback regulator implicating downregulation of proteinase (or protease)-activated receptor (PAR) expression and function by PGE2 production. G, 7-transmembrane domain G protein; TRAP, thrombin receptor activating peptide; IP3, inositol 1,4,5-trisphosphate; DAG, diacylglycerol; ROK, Rho kinase; JNK, c-Jun NH2-terminal kinase; p70, p70 s6k ; CaMK, calmodulin kinase II and IV; COX-2, cyclooxygenase-2. Ac, adenylyl cyclase; circled minus sign, inhibition.
PAR-1 and PAR-3; 3) treatment of human lung fibroblasts with thrombin, TRAP, and trypsin all increased [Ca 2ϩ ] cyt , indicating functional expression of PARs; 4) thrombin-mediated rise in [Ca 2ϩ ] cyt enhances PGE 2 synthesis and release by upregulating COX-2 expression; and 5) the thrombin-or TRAP-mediated PGE 2 release is significantly inhibited in fibrotic fibroblasts compared with normal fibroblasts.
As shown in Fig. 1 , thrombin-mediated proteolytic cleavage via the cleavage site facilitates the tethered ligand domain to interact with the extracellular loop-2 and activates the receptor (e.g., PAR-1). PAR activating peptides (e.g., TRAP), which include the various tethered ligand domains, can also activate the receptor by directly interacting with the extracellular loop-2 (without cleavage of the NH 2 terminus). The downstream signal transduction pathways vary in different cells and tissues. One of the critical pathways is the G q/11 -mediated increase in [Ca 2ϩ ] cyt that not only activates CaMKII (or CaMKIV) and PKC but upregulates mRNA and protein expression of COX-2 (see Ref. 19) . The increased amount of COX-2 enzyme and the Ca 2ϩ -mediated increase in COX-2 enzymatic activity both enhance the production of PGH 2 and PGE 2 (via the PGE synthase) and release of PGE 2 ( Fig. 1) . Extracellular or intercellular PGE 2 then activates the EP2 via an autocrine mechanism and increases cytoplasmic levels of cAMP.
Although cAMP can directly activate or inhibit certain types of ion channels in the plasma membrane, it exerts its effects mainly by activating cAMP-dependent protein kinase or PKA. The increased cAMP and activated PKA by PGE 2 and EP2 receptor activation not only "directly" inhibit thrombin-mediated fibroblast proliferation but also "indirectly" downregulate the mRNA expression of PARs (e.g., PAR-1, -2, -3) (Fig. 1 ) (19) . This negative feedback effect of thrombin on PAR expression via PGE 2 /EP2 receptor/cAMP-PKA cascade may play an important role in controlling the proliferative or fibrotic effects of thrombin and other serine proteases in normal lung fibroblasts.
In fibroblasts from patients with fibrosis, the authors (19) show that the mRNA expression of PAR-2 was upregulated, whereas the thrombin-(and TRAP-) mediated PGE 2 release is attenuated. The increased PAR-2 would enhance the thrombinmediated proliferative or fibrotic effects on pulmonary fibroblasts, whereas the inhibited PGE 2 would significantly facilitate or enhance the thrombin-mediated fibrotic effects. One of the important findings in this study is that inhibited negative feedback pathway, the thrombin-mediated PGE 2 release, and cAMP/PKA-mediated inhibitory effects on fibroblast proliferation and PAR expression may play a critical role in the development of pulmonary fibrosis.
The observations from this study also suggest an important concept: a pathogenic or etiological mechanism of a disease (e.g., pulmonary fibrosis) always includes a "triggering process" that mediates the transition from a normal to a diseased phenotype, accompanied by a positive-and a negative-feedback pathway that "ensure and control" the development (and progression) of the disease. Regulation or modulation of the feedback pathways not only plays an important role in the pathogenesis but also plays a pivotal role in developing therapeutic approaches for the disease. Searching for the sequences of events that are responsible for the phenotypical transition and progression of normal fibroblasts to fibrotic fibroblasts is important and may involve multiple factors and pathways.
